Invisible but Invalidating: Undisclosed Functionality Still Triggers On-Sale Bar
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Douglas B. Wentzel and Alex Martin del Campo
DEFINITIVE HOLDINGS, LLC v. POWERTEQ LLC
Before Moore, Dyk, and Cunningham. Appeal from the United States District Court for the District of Utah.
Summary: A third-party sale of a product embodying the claimed invention before the critical date can trigger the on-sale bar even if the product’s functionality was not publicly disclosed.
Definitive Holdings sued Powerteq alleging infringement of a patent directed to upgrading engine controller software. Powerteq moved for summary judgment of invalidity under the pre-AIA on-sale bar (35 U.S.C. § 102(b)), arguing that a third party, Hypertech, sold a device embodying the asserted claims more than one year before the patent’s priority date. The district court granted summary judgment, and Definitive appealed.
The Federal Circuit affirmed. The Federal Circuit agreed that the factual record, which Definitive did not dispute, established clear and convincing evidence Hypertech’s device was sold before the critical date and embodied every limitation of the asserted claims. The Federal Circuit also rejected Definitive’s argument that the on-sale bar requires public disclosure of the invention’s functionality. The court explained a commercial sale need not disclose how the invention works so long as the product sold embodies the claimed invention. Because Hypertech’s device was publicly sold and enabled users to perform the claimed methods, the on-sale bar applied.
Editor: Sean Murray
More insights
The Prosecution Data Most IP Attorneys Never Look At
Most prosecution strategy is set before anyone looks at who is actually examining the application. What is sitting there unused Every examiner has a history: allowance rate, average number of office actions, how often an interview changes the outcome. None…
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…